On July 10, Hims & Hers Health fell 5.36% in regular trading, trading at approximately $33.80 per share, with turnover of $142 million. The decline was triggered by multiple insider holding change declarations and proposed securities sale filings (Form 144), which intensified market selling sentiment.

The company has seen a series of insider transactions filed with the SEC in recent weeks, including numerous Form 4 ownership change statements and Form 144 proposed sale notices dating from mid-June through early July. These filings signal potential insider liquidation, compounding bearish pressure on the stock.

The stock continues to face fundamental headwinds following a Q1 net loss of $92 million reported in May, which widened from $50 million a year earlier. Additionally, Bank of America recently lowered its price target to $25 from $28. While the company completed its acquisition of Eucalyptus in June to expand internationally and launched generic semaglutide in Canada, elevated investment spending and a $300 million convertible notes offering have weighed on investor confidence regarding near-term profitability.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)